Is It Reliable to Take the Molecular Docking Top Scoring Position as the Best Solution without Considering Available Structural Data?

Molecular docking is the most frequently used computational method for studying the interactions between organic molecules and biological macromolecules. In this context, docking allows predicting the preferred pose of a ligand inside a receptor binding site. However, the selection of the “best” solution is not a trivial task, despite the widely accepted selection criterion that the best pose corresponds to the best energy score. Here, several rigid-target docking methods were evaluated on the same dataset with respect to their ability to reproduce crystallographic binding orientations, to test if the best energy score is a reliable criterion for selecting the best solution. For this, two experiments were performed: (A) to reconstruct the ligand-receptor complex by performing docking of the ligand in its own crystal structure receptor (defined as self-docking), and (B) to reconstruct the ligand-receptor complex by performing docking of the ligand in a crystal structure receptor that contains other ligand (defined as cross-docking). Root-mean square deviation (RMSD) was used to evaluate how different the obtained docking orientation is from the corresponding co-crystallized pose of the same ligand molecule. We found that docking score function is capable of predicting crystallographic binding orientations, but the best ranked solution according to the docking energy is not always the pose that reproduces the experimental binding orientation. This happened when self-docking was achieved, but it was critical in cross-docking. Taking into account that docking is typically used with predictive purposes, during cross-docking experiments, our results indicate that the best energy score is not a reliable criterion to select the best solution in common docking applications. It is strongly recommended to choose the best docking solution according to the scoring function along with additional structural criteria described for analogue ligands to assure the selection of a correct docking solution.

[1]  Y Li,et al.  Crystal structure of human alpha-thrombin complexed with hirugen and p-amidinophenylpyruvate at 1.6 A resolution. , 1995, Archives of biochemistry and biophysics.

[2]  Julio Caballero,et al.  Docking and quantitative structure–activity relationship studies for sulfonyl hydrazides as inhibitors of cytosolic human branched-chain amino acid aminotransferase , 2009, Molecular Diversity.

[3]  W. L. Jorgensen,et al.  Development and Testing of the OPLS All-Atom Force Field on Conformational Energetics and Properties of Organic Liquids , 1996 .

[4]  Julio Caballero,et al.  Investigation of the Differences in Activity between Hydroxycycloalkyl N1 Substituted Pyrazole Derivatives As Inhibitors of B-Raf Kinase by Using Docking, Molecular Dynamics, QM/MM, and Fragment-Based De Novo Design: Study of Binding Mode of Diastereomer Compounds , 2011, J. Chem. Inf. Model..

[5]  Amy L. Lane,et al.  Optimization of peptide hydroxamate inhibitors of insulin-degrading enzyme reveals marked substrate-selectivity. , 2013, Journal of medicinal chemistry.

[6]  David S. Goodsell,et al.  A semiempirical free energy force field with charge‐based desolvation , 2007, J. Comput. Chem..

[7]  Richard A. Lewis,et al.  Lessons in molecular recognition: the effects of ligand and protein flexibility on molecular docking accuracy. , 2004, Journal of medicinal chemistry.

[8]  Julio Caballero,et al.  Study of the Differential Activity of Thrombin Inhibitors Using Docking, QSAR, Molecular Dynamics, and MM-GBSA , 2015, PloS one.

[9]  Fernando D. González Nilo,et al.  Insights into the Structural Basis of N2 and O6 Substituted Guanine Derivatives as Cyclin-Dependent Kinase 2 (CDK2) Inhibitors: Prediction of the Binding Modes and Potency of the inhibitors by Docking and ONIOM Calculations , 2009, J. Chem. Inf. Model..

[10]  Didier Rognan,et al.  Comparative evaluation of eight docking tools for docking and virtual screening accuracy , 2004, Proteins.

[11]  G. Klebe,et al.  Knowledge-based scoring function to predict protein-ligand interactions. , 2000, Journal of molecular biology.

[12]  Mike Welch,et al.  Potent and selective pyrazole-based inhibitors of B-Raf kinase. , 2008, Bioorganic & medicinal chemistry letters.

[13]  R. Kroemer Structure-based drug design: docking and scoring. , 2007, Current protein & peptide science.

[14]  J. Bajorath,et al.  Docking and scoring in virtual screening for drug discovery: methods and applications , 2004, Nature Reviews Drug Discovery.

[15]  M. Mezei,et al.  Molecular docking: a powerful approach for structure-based drug discovery. , 2011, Current computer-aided drug design.

[16]  Andrea Mattevi,et al.  Three-dimensional structure of human monoamine oxidase A (MAO A): relation to the structures of rat MAO A and human MAO B. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[17]  Gennady Verkhivker,et al.  Deciphering common failures in molecular docking of ligand-protein complexes , 2000, J. Comput. Aided Mol. Des..

[18]  Peter Riederer,et al.  MAO-inhibitors in Parkinson's Disease , 2011, Experimental neurobiology.

[19]  Robert J. Doerksen,et al.  Docking Challenge: Protein Sampling and Molecular Docking Performance , 2013, J. Chem. Inf. Model..

[20]  Julio Caballero,et al.  Computational study of the binding orientation and affinity of PPARγ agonists: inclusion of ligand-induced fit by cross-docking , 2016 .

[21]  Garland R. Marshall,et al.  An Automated Strategy for Binding-Pose Selection and Docking Assessment in Structure-Based Drug Design , 2016, J. Chem. Inf. Model..

[22]  I. Waizenegger,et al.  A Novel RAF Kinase Inhibitor with DFG-Out–Binding Mode: High Efficacy in BRAF-Mutant Tumor Xenograft Models in the Absence of Normal Tissue Hyperproliferation , 2016, Molecular Cancer Therapeutics.

[23]  Matthew P. Repasky,et al.  Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. , 2006, Journal of medicinal chemistry.

[24]  Peng Xie,et al.  Identification of a novel family of BRAF(V600E) inhibitors. , 2012, Journal of medicinal chemistry.

[25]  R. Friesner,et al.  Evaluation and Reparametrization of the OPLS-AA Force Field for Proteins via Comparison with Accurate Quantum Chemical Calculations on Peptides† , 2001 .

[26]  E. Laird,et al.  Non-oxime inhibitors of B-Raf(V600E) kinase. , 2011, Bioorganic & medicinal chemistry letters.

[27]  Giulio Rastelli,et al.  Structure-based design of potent aromatase inhibitors by high-throughput docking. , 2011, Journal of medicinal chemistry.

[28]  Kenichi A Tanaka,et al.  Blood Coagulation: Hemostasis and Thrombin Regulation , 2009, Anesthesia and analgesia.

[29]  Alba Chimirri,et al.  Induced‐Fit Docking Approach Provides Insight into the Binding Mode and Mechanism of Action of HIV‐1 Integrase Inhibitors , 2009, ChemMedChem.

[30]  Gerhard Klebe,et al.  Fragment Binding Can Be Either More Enthalpy-Driven or Entropy-Driven: Crystal Structures and Residual Hydration Patterns Suggest Why. , 2015, Journal of medicinal chemistry.

[31]  David S. Goodsell,et al.  AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility , 2009, J. Comput. Chem..

[32]  Hege S. Beard,et al.  Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. , 2004, Journal of medicinal chemistry.

[33]  C. Pritchard,et al.  Raf proteins and cancer: B-Raf is identified as a mutational target. , 2003, Biochimica et biophysica acta.

[34]  Roberta Menabò,et al.  Monoamine oxidases (MAO) in the pathogenesis of heart failure and ischemia/reperfusion injury. , 2011, Biochimica et biophysica acta.

[35]  Andrea Mattevi,et al.  Binding of rasagiline-related inhibitors to human monoamine oxidases: a kinetic and crystallographic analysis. , 2005, Journal of medicinal chemistry.

[36]  Gerhard Klebe,et al.  Ligand binding stepwise disrupts water network in thrombin: enthalpic and entropic changes reveal classical hydrophobic effect. , 2012, Journal of medicinal chemistry.

[37]  G Klebe,et al.  Impact of ligand and protein desolvation on ligand binding to the S1 pocket of thrombin. , 2012, Journal of molecular biology.

[38]  Andrea Mattevi,et al.  Insights into the mode of inhibition of human mitochondrial monoamine oxidase B from high-resolution crystal structures , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[39]  D S Goodsell,et al.  Automated docking of flexible ligands: Applications of autodock , 1996, Journal of molecular recognition : JMR.

[40]  James Tsai,et al.  RAF inhibitors that evade paradoxical MAPK pathway activation , 2015, Nature.

[41]  S Alban,et al.  Pharmacological strategies for inhibition of thrombin activity. , 2008, Current pharmaceutical design.

[42]  Peter Florian,et al.  5-Chlorothiophene-2-carboxylic acid [(S)-2-[2-methyl-3-(2-oxopyrrolidin-1-yl)benzenesulfonylamino]-3-(4-methylpiperazin-1-yl)-3-oxopropyl]amide (SAR107375), a selective and potent orally active dual thrombin and factor Xa inhibitor. , 2013, Journal of medicinal chemistry.

[43]  Tomoyasu Ishikawa,et al.  Discovery of a selective kinase inhibitor (TAK-632) targeting pan-RAF inhibition: design, synthesis, and biological evaluation of C-7-substituted 1,3-benzothiazole derivatives. , 2013, Journal of medicinal chemistry.

[44]  Matthew P. Repasky,et al.  Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. , 2004, Journal of medicinal chemistry.

[45]  Hieu T. Do,et al.  Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. , 2006, Cancer research.

[46]  Gerhard Klebe,et al.  Fragments Can Bind Either More Enthalpy or Entropy-Driven: Crystal Structures and Residual Hydration Pattern Suggest Why. , 2015 .

[47]  Tamás Tábi,et al.  Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson’s disease , 2018, Journal of Neural Transmission.

[48]  P Théroux,et al.  Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. , 1998, Circulation.

[49]  Yong Zhou,et al.  Roll: a new algorithm for the detection of protein pockets and cavities with a rolling probe sphere , 2010, Bioinform..

[50]  Woody Sherman,et al.  Generation of Receptor Structural Ensembles for Virtual Screening Using Binding Site Shape Analysis and Clustering , 2012, Chemical biology & drug design.

[51]  Kam Y. J. Zhang,et al.  Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity , 2008, Proceedings of the National Academy of Sciences.

[52]  Andrea Mattevi,et al.  Structural and mechanistic studies of mofegiline inhibition of recombinant human monoamine oxidase B. , 2008, Journal of medicinal chemistry.

[53]  Mark R Player,et al.  2-(2-Chloro-6-fluorophenyl)acetamides as potent thrombin inhibitors. , 2007, Bioorganic & medicinal chemistry letters.

[54]  Andrea Mattevi,et al.  Molecular Insights into Human Monoamine Oxidase B Inhibition by the Glitazone Anti-Diabetes Drugs. , 2012, ACS medicinal chemistry letters.

[55]  Julio Caballero,et al.  Insights into the Interactions between Maleimide Derivates and GSK3β Combining Molecular Docking and QSAR , 2014, PloS one.

[56]  Julio Caballero,et al.  Is It Reliable to Use Common Molecular Docking Methods for Comparing the Binding Affinities of Enantiomer Pairs for Their Protein Target? , 2016, International journal of molecular sciences.

[57]  Alan P Graves,et al.  GSK114: A selective inhibitor for elucidating the biological role of TNNI3K. , 2016, Bioorganic & medicinal chemistry letters.

[58]  Maryse Lowinski,et al.  The use of virtual screening and differential scanning fluorimetry for the rapid identification of fragments active against MEK1. , 2013, Bioorganic & medicinal chemistry letters.

[59]  Julio Caballero,et al.  Docking and quantitative structure–activity relationship studies for imidazo[1,2-a]pyrazines as inhibitors of checkpoint kinase-1 , 2011, Medicinal Chemistry Research.

[60]  David Ramírez Computational Methods Applied to Rational Drug Design , 2016, The open medicinal chemistry journal.

[61]  Julio Caballero,et al.  Computational Study on the Interaction of N1 Substituted Pyrazole Derivatives with B-Raf Kinase: An Unusual Water Wire Hydrogen-Bond Network and Novel Interactions at the Entrance of the Active Site , 2010, J. Chem. Inf. Model..

[62]  K. Stringer,et al.  Hirudins: Antithrombin Anticoagulants , 1992, The Annals of pharmacotherapy.

[63]  B. Tomczuk,et al.  Oxyguanidines. Part 2: Discovery of a novel orally active thrombin inhibitor through structure-based drug design and parallel synthesis. , 2004, Bioorganic & medicinal chemistry letters.

[64]  Mathew J Garnett,et al.  Guilty as charged: B-RAF is a human oncogene. , 2004, Cancer cell.

[65]  Elizabeth Yuriev,et al.  Latest developments in molecular docking: 2010–2011 in review , 2013, Journal of molecular recognition : JMR.

[66]  Nanxin Li,et al.  B-Raf kinase inhibitors for cancer treatment. , 2007, Current opinion in investigational drugs.

[67]  G. V. Paolini,et al.  Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes , 1997, J. Comput. Aided Mol. Des..

[68]  Angelo Carotti,et al.  Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs. , 2007, Journal of medicinal chemistry.

[69]  Mirko Zimic,et al.  Docking and quantitative structure–activity relationship studies for 3-fluoro-4-(pyrrolo[2,1-f][1,2,4]triazin-4-yloxy)aniline, 3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)aniline, and 4-(4-amino-2-fluorophenoxy)-2-pyridinylamine derivatives as c-Met kinase inhibitors , 2011, J. Comput. Aided Mol. Des..

[70]  Michal Vieth,et al.  Lessons in Molecular Recognition, 2. Assessing and Improving Cross-Docking Accuracy , 2007, J. Chem. Inf. Model..

[71]  Andrea Mattevi,et al.  Crystal structures of monoamine oxidase B in complex with four inhibitors of the N-propargylaminoindan class. , 2004, Journal of medicinal chemistry.